Posted by Michael Wonder on 01 Jul 2020
NICE publishes final guidance for Tecentriq for 2 indications
1 July 2020 - NICE has released final guidance on the use of atezolizumab by patients with small cell lung cancer and by patients with breast cancer.
Atezolizumab with carboplatin and etoposide is recommended as an option for untreated extensive-stage small-cell lung cancer in adults, only if:
- they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and
- Roche provides atezolizumab according to the commercial arrangement.
Atezolizumab with nab‑paclitaxel is recommended, within its marketing authorisation, for treating triple-negative, unresectable, locally advanced or metastatic breast cancer in adults whose tumours express PD‑L1 at a level of 1% or more and who have not had previous chemotherapy for metastatic disease. It is recommended only if the company provides atezolizumab according to the commercial arrangement.
